Satellite Symposia (Updated February 9, 2016)
Thursday, March 3, 2016
Pertussis - The Protection Starts with You
Sponsored by GlaxoSmithKline
Thursday, March 3, 2016, 12:30 - 14:15hrs, Hall 6 (Ground Level)
    Welcome and Introductions

    Panel discussion including the following topics:
  • Latest update on global and regional pertussis burden
  • Why pertussis is a public health concern
  • Current recommendations and available strategies for pertussis prevention in different age group
  • Lessons learned from pertussis vaccination implementation
    Panelists: Anil Dutta (Belgium); Walid Kandeil (Belgium); Tomas Marcek (Belgium)

    Interactive session with audience

    Concluding remarks and Q&A
Friday, March 4, 2016

Do MMRV Combination Vaccines Optimize the Prevention of Measles, Mumps, Rubella and Varicella?
Sponsored by GlaxoSmithKline
Friday, March 4, 2016, 18:00 - 20:00hrs, Hall 6 (Ground Level)

  • Introduction
    Anil Dutta (Belgium); Sanjay Lalwani (India)
  • Lessons learned from MMRV combination vaccine programs worldwide
    Volker Vetter (Belgium)
  • Recent evidence from India
    Sanjay Lalwani (India)
  • Panel Discussion: The potential role of MMRV vaccination in India
    Anil Dutta (Belgium); Sanjay Lalwani (India); Volker Vetter (Belgium)
  • Q&A and concluding remarks
    Anil Dutta (Belgium)
Friday, March 4, 2016
Pneumococcal Disease Prevention: Further Evidence of Success
Sponsored by Pfizer
Friday, March 4, 2016, 12:30 - 14:15hrs, Hall 6 (Ground Level)
  • Opening Remarks
    Mark A. Fletcher (France)

    PCV Protection of Children: A Story of Immune Response, Serotype by Serotype
  • Helping to Protect Against Pneumococcal Disease Across Generations: Public Health Impact of PCVs
    Nitin Shah (India)

    Pneumococcal Vaccination in Older Adults: Where Is The Evidence Leading?
  • The Burden of Pneumococcal Pneumonia In Adult Populations: Recognizing an Unmet Need
    Rosana Ritchmann (Brazil)
  • Helping to Protect Adults Against Pneumococcal Pneumonia: From Clinical Trials to Vaccine Policy
    Charles Feldman (South Africa)

  • Summary and Concluding Remarks
    Mark A. Fletcher (France)
       Return to Top